cardiology-congress-microbe-infection-2018-tracks

15 / 15

Page 36
J u l y 2 3 - 2 4 , 2 0 1 8 | R o m e , I t a l y
Note:
alliedacademies Joint Event on
Cardiology Congress 2018 & Microbe Infection 2018 Biomedical Research | ISSN: 0976-1683 | Volume 29
2nd World Congress on CARDIOLOGY
MICROBIOLOGY AND MICROBIAL INFECTION
&
39th Annual Congress on
Giulio Tarro, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C1-002
EPIDEMIC FLU VIRUS
Giulio Tarro
Foundation de Beaumont Bonelli for Cancer Research, Italy
For the emergency created by the epidemic of influence of the pigs in
Mexico it was correct not to create alarmism’s being victims of a bad
information. The possibility that the virus arrives in other parts of the world
is real as for all the types of influence virus. In order that a strain has a wide
distribution, its antigenic characteristics must ensure that it escapes the
neutralization of antibodies of the host and of the surrounding population.
So, the outbreaks will happen with those strains that have dominant antigens
that fit the deficiency, or better, the absences of antibody in the population.
It seems, in conclusion that the flu virus shows an ability and an aptitude
for survival built on the possibility of emergence of new models that allow
the virus being confused easily through populations still partly immune to
previous antigenic forms. According to this view, the changes in the influenza
A can be designed in single meaning, in the context of a principle and of
an evolutionary progress, from Burnet said immunological drift or steering
immunology. The antiviral drugs (inhibitors of the neuraminidases, receptor
of the virus surface) should be assumed within 48 hours by the appearance
of the influence symptoms and for the subjects that have had a close contact
with people infected by the flu virus. The vaccination against the influence is
the most effective method to prevent the illness. From the moment that we
find the isolation of a new flu virus, we must wait for the preparation of a new
specific vaccine that will be ready for the next influence season in Autumn.
Giulio Tarro is graduated from Medicine School, Na-
ples University (1962). He is the Research Associate,
Division of Virology and Cancer Research, Children’s
Hospital (1965-1968), Assistant Professor of Re-
search Pediatrics, College of Medicine (1968-1969),
Cincinnati University, Ohio. He is also the Oncological
Virology Professor, Naples University (1972-1985).
Chief Division Virology (1973-2003), Head Depart-
ment Diagnostic Laboratories, (2003-2006). Since
2007, he was the Chairman of Committee of Biotech-
nologies and VirusSphere, World Academy Biomedi-
cal Technologies, UNESCO, Adjunct Professor Depart-
ment of Biology, Temple University, College of Science
and Technology, Philadelphia, recipient of the Sbarro
Health Research Organization lifetime achievement
award (2010). His researches have been concerned
with the characterization of specific virus-induced tu-
mor antigens, which were the finger-prints left behind
in human cancer. Achievements include patents in
field; discovery of respiratory syncytial virus in infant
deaths in Naples and of tumor liberated protein as a
tumor associated antigen, 55 kilodalton protein over-
expressed in lung tumors and other epithelial adeno-
carcinomas.
BIOGRAPHY